Jade Biosciences, Inc. 8-K

What Happened
On June 29, 2026, Jade Biosciences, Inc. announced it entered the JADE301 License Agreement with Paragon Therapeutics, granting Jade a worldwide, exclusive, sublicensable license to certain monospecific antibodies (targeting an undisclosed “Target”) for prophylaxis, palliation, treatment and diagnosis across all therapeutic areas. The deal is royalty-bearing and includes development/regulatory milestones and sublicensing commercial milestones; the agreement will be filed as an exhibit to Jade’s Form 10‑Q for the quarter ending June 30, 2026.

Key Details

• Agreement date: June 29, 2026; license from Paragon Therapeutics, Inc.
• Milestones: up to $22.0 million in development/regulatory milestones (includes a $1.5M candidate nomination fee paid in Jan 2026 and a $2.5M payment upon first dosing in a Phase 1 trial).
• Sublicense commercial milestones: up to approximately $20.1 million per product.
• Royalties: low- to mid-single-digit % on monospecific product sales and mid-single-digit % on multispecific product sales; royalty reduced by 30% in countries where no valid patent covers the product. Royalty term ends country-by-country on the later of the 12th anniversary of first sale or expiration of the last-to-expire valid patent.
• Exclusivity/IP carveout: Paragon will not run new campaigns to generate monospecific antibodies against the Target in the Field for at least five years. Termination rights include 60 days’ notice by Jade, material breach without cure, and insolvency/bankruptcy provisions.

Why It Matters
This agreement gives Jade exclusive rights to develop and commercialize an antibody program without a large upfront payment, tying costs to development, regulatory progress and commercial milestones. For investors, the arrangement limits near-term cash outlays to milestone-triggered payments and ongoing royalties, while potentially adding a new pipeline opportunity if development advances (notably a $2.5M payment is due at first human dosing). Royalty rates and a 30% reduction tied to patent coverage highlight the importance of intellectual property and future patent status to commercial returns. The deal’s exclusivity and Paragon’s five-year restraint reduce near-term competitive risk on the same target from Paragon.